Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FNMNS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,465
Award facts
- Contract value 100% obligated
- $9,464.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $9,464.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of NUCALA 100 MG/ML syringes. DMS Pharmaceutical Group is a long-standing federal contractor registered in the System for Award Management since 2001 and specializes in distributing comprehensive pharmaceutical products and medical consumables to the Department of Defense. This delivery order was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award carries a firm fixed-price structure with an ultimate completion date of November 10, 2025, and performance will be conducted at the company's location in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was recently awarded on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036. The PPV-G GEN V represents a critical acquisition vehicle supporting the Department of Defense's recurring medical supply requirements, with DMS Pharmaceutical Group positioned as one of multiple regional prime vendor contractors within the broader $30.3 billion program. NUCALA, an immunosuppressant biologic agent, is among the specialized pharmaceuticals the contractor routinely supplies to military healthcare facilities worldwide through this indefinite delivery contract structure.
Quick answers
Who was awarded contract SPE2DB26FNMNS?
SPE2DB26FNMNS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FNMNS worth?
The government has obligated $9,465 on SPE2DB26FNMNS.
Is contract SPE2DB26FNMNS an order under another contract?
Yes. SPE2DB26FNMNS is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNS competed?
The extent of competition for SPE2DB26FNMNS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award